ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

DCPC Advisors OK PA On cancer Control In Disadvantaged

June 14, 1991

NIH Authorization Bills Require NCI To Spend 10% On Cancer control

February 12, 1993

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

In Brief: FDA Names DeLap Directory Of Oncology

June 7, 1996

HOP Development Proceeding Guidelines For New, Revision Of Existing Control Grants Being Written

July 24, 1981

Wynder Group Finds No Association Between Coffee, Pancreatic Cancer

August 19, 1983